RILIF MR TABLETS

Class: NSAID, Analgesic, Muscle relaxant

Manufacturer: Dawa Limited, Baba Dogo Road, Ruaraka, Nairobi, Kenya

Dosage Form: Tablet

Similar Brands: Zulu MR

Uses:

Rilif mr is indicated for the relief of pain and inflammation association with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, low back pains, tendinitis, torticolis, myositis, bursitis, sprots injuries, frozen shoulder, fibrositis, sprain.

Dosage:

The dose of RILIF MR is 1 tablet twice daily by mouth. One tablet in the morning and one in the evening. There is some evidence that the dose of RILIF MR should be reduced in patients with hepatic impairment and it is suggested that that an initial daily dose of 1 tablet to be taken used. RILIF MR tablets should be swallowed whole with a sufficient quantity of liquids. It can be taken along with food.

Side Effects:

RILIF MR is generally well tolerated. The majority of adverse reactions reported have been reversible and of a minor nature. The most frequent are gastro-intestinal disorders, in particular dyspepsia, abdominal pain, nausea, diarrhea, and occasional occurrence of dizziness. Dermatological complaints including pruritus and rash and abdominal hepatic enzyme and serum creatinine levels have also been reported. If serious adverse reactions occur, RILIF MR should be withdrawn.

Warnings & Precautions:

Close medical surveillance is imperative in patients with symptoms indicative of gastrointestinal disorders, with a history suggestive of gastrointestinal ulceration, with ulcerative colitis and Crohn’s disease, bleeding diathesis or hematological abnormalities. Gastrointestinal bleeding or ulcerative perforation, haematesis and malaena have in general more serious consequences in the elderly, in rare event, where gastrointestinal bleeding or ulceration occurs in patients receiving rilif mr, the drug should be withdrawn. Close medical surveillance is also imperative in patients suffering from severe impairment of hepatic function.

Over dosage

Management of acute poisoning with NSAIDs essentially consists of supportive and symptomatic measures.

RILIF MR should be given with caution to the elderly patients with renal, hepatic or cardiovascular impairment and to those receiving other medication. The lowest effective dose should be used and renal function monitored regularly. As with other NSAIDs allergic reactions, including anaphylactic/anaphylactoid reactions, can occur without earlier exposure to the drug. Caution should also be exercised in patients with history of coagulation defects and history of liver dysfunction. Renal and hepatic function and blood counts should be monitored during long term treatment. Persistently elevated hepatic enzymes levels necessitate withdrawal of RILIF MR.

Renal impairment

Patients with mild renal impairment should be kept under surveillance since the use of NSAIDs may result in deterioration of renal function. The lowest effective dose should be used and renal function monitored regularly.

Hepatic impairment

Dose of RILIF MR should be reduced in patients with impaired liver function.

If abnormal liver function tests persist or worsen, clinical signs or symptoms consistent with liver disease develop or if other manifestations occur (eosinophilia, rash), RILIF MR should be discontinued. Hepatitis may occur without prodromal symptoms.

Pediatric use

There are no clinical data on the use of RILIF MR in children.

Pregnancy & Lactation:

Use of systemic NSAIDs during late pregnancy may lead to delayed labor and premature closure of ductus arteriosus. It has also been found in the breast milk of nursing mothers. There is not information on the use of RILIF MR in pregnant and lactating patients. The drug in not recommended in pregnant and lactating women

Drug Interactions:

Drug interactions are similar to those observed with commonly used NSAIDs. Aceclofenac may increase plasma concentrations of lithium, digoxin and methotrexate, increase the activity of anticoagulants, inhibit the activity of diureticsm, enhance cyclosporine nephrotoxicity and precipitate convulsions when co-administered with quinolone antibiotics. When concomitant administration of potassium sparing diuretics is employed, serum potassium should be monitored. Furthermore, hypo or hyperglycemia may result from the concomitant administration of aceclofenac and antidiabetic drugs, although this is rare. The co-administration of aceclofenac with other NSAIDs or corticosteroids may result in increased frequency of side effects. Caution should be exercised if NSAIDs and methotrexate are administered within 2-4 hours of each other, since NSAIDs may increase methotrexate plasma levels, resulting in increased toxicity.

Contraindications:

RILIF MR should not be administered to patients hypersensitive to any of the ingredients or other NSAIDs, or patients with history of aspirin or NSAID related allergic or anaphylactic reactions or with peptic ulcers or GI bleeding, moderate or severe renal impairment or asthma

Price: Ksh 760

Notes:

Pack Size: 20s

Distributed by: Medisel (Kenya) Limited.